Gilenya, developed by Novartis Pharmaceuticals, was the first oral disease-modifying therapy to obtain U.S. and European approval. The Food and Drug Administration and European Medicines Agency authorized it for reducing the frequency of relapses and delaying progression of relapsing-remitting multiple sclerosis (RRMS).
Their decisions were supported by the results of three Phase 3 clinical trials: FREEDOMS (NCT00289978), FREEDOMS II (NCT00355134), and TRANSFORMS (NCT00340834). The trials explored the effectiveness and safety of Gilenya in comparison with Avonex (interferon beta-1a) and a placebo.
Researchers from Spain have confirmed the trial results in a study titled “The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study.” It covered 249 MS patients treated for a mean of 33.1 months.
The patients were divided into three groups, according to their previous MS treatment: treatment with Copaxone/interferon beta-1 (immunomodulator), treatment with Tysabri (natalizumab), or no previous treatment.
Gilenya reduced patients’ annual relapse rate in the first 24 months by 75 percent. The figures were 67 percent of patients previously treated with immunomodulators, such as Avonex, Copaxone or Tysabri, and 85 percent in patients who had never been treated.
The results were independent of patients’ age when they began receiving Gilenya, the number of their previous treatments, their gender, the number of their brain lesions, and their basal disability score. The basal ganglia is an area of the brain that controls movement. Scientists use the Expanded Disability Status Scale (EDSS) to assess damage to the ganglia.
“Although fingolimod [Gilenya] benefits MS patients regardless of the EDSS score at the treatment initiation, our data suggest that patients with basal EDSS score of <3 might have better outcomes,” the researchers wrote. The scale runs from 0 to 10, with 0 meaning no disability.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?